5-Amino-1MQ (50 mg Vial) Dosage Protocol
Quickstart Highlights
5-Amino-1MQ dosage protocols center on this selective, cell-permeable NNMT (Nicotinamide N-methyltransferase) inhibitor studied for its potential to support fat metabolism, preserve lean muscle mass, and elevate intracellular NAD+ levels. By blocking NNMT, 5-Amino-1MQ may help restore cellular energy balance and activate SIRT1 pathways associated with metabolic efficiency. This educational protocol presents a subcutaneous injection approach to maximize bioavailability from the 50 mg vial format.
- Reconstitute: Add 4.0 mL bacteriostatic water → 12.5 mg/mL concentration.
- Typical daily range: 2.5–5 mg once or twice daily (subcutaneous).
- Easy measuring: At 12.5 mg/mL, 1 unit = 0.01 mL = 0.125 mg (125 mcg) on a U-100 insulin syringe.
- Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and use within 2–4 weeks.
Subcutaneous Protocol (4 mL = 12.5 mg/mL)
| Phase | Daily Dose (mg) | Units (per injection) (mL) |
|---|---|---|
| Days 1–2 (Tolerance) | 2.5 mg once daily | 20 units (0.20 mL) |
| Days 3+ (Standard) | 5 mg once daily | 40 units (0.40 mL) |
| Alternative BID | 2.5 mg twice daily | 20 units (0.20 mL) × 2 |
Frequency: Inject once or twice daily subcutaneously. Due to the compound’s plasma half-life of approximately 3.8–6.9 hours, twice-daily (BID) dosing may provide more sustained NNMT inhibition. A single 50 mg vial provides 10–20 days of research material at these doses.
Reconstitution Steps
- Remove the vial from freezer storage (−20 °C / −4 °F) and allow to equilibrate at room temperature for 15–20 minutes.
- Draw 4.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved—solution should be clear (do not shake).
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light; use within 2–4 weeks.
Supplies Needed
Plan based on research duration using the 50 mg vial format at 5 mg/day.
- 5-Amino-1MQ Vials (50 mg each): 1 week = 1 vial, 2 weeks = 1 vial, 4 weeks = 2 vials.
- Insulin Syringes (U-100): Per week (once daily) = 7 syringes.
- Bacteriostatic Water (10 mL bottles): Use 4.0 mL per vial for reconstitution.
- Alcohol Swabs: One for vial stopper + one for injection site.
Protocol Overview
Concise summary of the subcutaneous regimen.
- Goal: Support metabolic efficiency through NNMT inhibition, potentially enhancing fat oxidation and NAD+ levels.
- Schedule: Daily subcutaneous injections; each 50 mg vial provides 10–20 days of research material.
- Dose Range: 2.5–5 mg once or twice daily.
- Reconstitution: 4.0 mL per 50 mg vial (12.5 mg/mL) for accurate measurements.
- Storage: Lyophilized frozen at −20 °C (−4 °F); reconstituted refrigerated at 2–8 °C (35.6–46.4 °F).
How This Works
5-Amino-1MQ (5-amino-1-methylquinolinium) is a synthetic small molecule that selectively inhibits Nicotinamide N-methyltransferase (NNMT). NNMT is an enzyme that methylates nicotinamide (vitamin B3) using S-adenosylmethionine (SAM) as a methyl donor. In states of obesity and metabolic dysfunction, NNMT is often overexpressed in adipose tissue, depleting nicotinamide and reducing NAD+ availability.
By inhibiting NNMT, 5-Amino-1MQ may spare nicotinamide for NAD+ synthesis, thereby activating SIRT1 pathways associated with mitochondrial biogenesis and fat oxidation. Preclinical studies indicate that NNMT knockdown or inhibition can protect against diet-induced weight gain.
Important Note
This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment.
References
— Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity
View Source— Nicotinamide N-methyltransferase inhibition mitigates obesity-related metabolic dysfunctions
View Source